tradingkey.logo

Danaher Corp

DHR

188.540USD

-1.510-0.79%
Close 09/15, 16:00ETQuotes delayed by 15 min
134.98BMarket Cap
39.55P/E TTM

Danaher Corp

188.540

-1.510-0.79%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-15

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
38 / 207
Overall Ranking
142 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 26 analysts
Buy
Current Rating
242.621
Target Price
+27.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 20.13%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 20.13%.
Fairly Valued
The company’s latest PE is 39.77, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 670.76M shares, increasing 0.05% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 60.48M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.06.

Financial Health

Currency: USD Updated2025-09-15

The company's current financial score is 8.24, which is higher than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 5.74B, representing a year-over-year decrease of 0.95%, while its net profit experienced a year-over-year decrease of 12.32%.

Score

Industry at a Glance

Previous score
8.24
Change
-0.14

Financials

7.90

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.84

Operational Efficiency

8.20

Growth Potential

7.48

Shareholder Returns

9.11

Company Valuation

Currency: USD Updated2025-09-15

The company’s current valuation score is 1.80, which is lower than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 43.24, which is -3.52% below the recent high of 41.72 and 12.83% above the recent low of 37.69.

Score

Industry at a Glance

Previous score
1.80
Change
0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 38/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-15

The company’s current earnings forecast score is 8.67, which is higher than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Danaher Corp is 237.50, with a high of 310.00 and a low of 205.00.

Score

Industry at a Glance

Previous score
8.69
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 26 analysts
Buy
Current Rating
242.621
Target Price
+27.66%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Danaher Corp
DHR
26
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-15

The company’s current price momentum score is 7.13, which is lower than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 215.25 and the support level at 193.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.40
Change
-0.15

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-3.725
Sell
RSI(14)
33.533
Neutral
STOCH(KDJ)(9,3,3)
10.247
Oversold
ATR(14)
4.866
High Vlolatility
CCI(14)
-136.122
Sell
Williams %R
93.280
Oversold
TRIX(12,20)
-0.187
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
192.134
Sell
MA10
196.177
Sell
MA20
202.008
Sell
MA50
200.785
Sell
MA100
198.300
Sell
MA200
208.027
Sell

Institutional Confidence

Currency: USD Updated2025-09-15

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 93.67%, representing a quarter-over-quarter increase of 0.20%. The largest institutional shareholder is The Vanguard, holding a total of 60.48M shares, representing 8.45% of shares outstanding, with 2.13% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
The Vanguard Group, Inc.
Star Investors
59.70M
+0.39%
Rales (Steven M)
42.24M
-2.87%
Rales (Mitchell P)
34.93M
-0.58%
BlackRock Institutional Trust Company, N.A.
29.65M
+1.15%
State Street Global Advisors (US)
27.46M
+0.29%
Wellington Management Company, LLP
17.70M
-16.97%
Capital International Investors
15.06M
-14.72%
T. Rowe Price Associates, Inc.
Star Investors
18.64M
+3.30%
Geode Capital Management, L.L.C.
13.64M
+2.14%
Fidelity Management & Research Company LLC
12.56M
-33.11%
1
2

Risk Assessment

Currency: USD Updated2025-09-15

The company's beta value is 0.75. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.68
Change
0
Beta vs S&P 500 index
0.78
VaR
+2.69%
240-Day Maximum Drawdown
+37.18%
240-Day Volatility
+31.31%
Return
Best Daily Return
60 days
+4.20%
120 days
+9.88%
5 years
+9.88%
Worst Daily Return
60 days
-3.55%
120 days
-8.15%
5 years
-9.73%
Sharpe Ratio
60 days
-0.45
120 days
-0.47
5 years
+0.11
Risk Assessment
Maximum Drawdown
240 days
+37.18%
3 years
+37.80%
5 years
+40.73%
Return-to-Drawdown Ratio
240 days
-0.85
3 years
-0.14
5 years
-0.03
Skewness
240 days
-0.31
3 years
-0.06
5 years
+0.05
Volatility
Realised Volatility
240 days
+31.31%
5 years
+28.68%
Standardised True Range
240 days
+2.92%
5 years
+2.94%
Downside Risk-Adjusted Return
120 days
-67.58%
240 days
-67.58%
Maximum Daily Upside Volatility
60 days
+22.21%
Maximum Daily Downside Volatility
60 days
+20.50%
Liquidity
Average Turnover Rate
60 days
+0.54%
120 days
+0.55%
5 years
--
Turnover Deviation
20 days
-5.52%
60 days
+18.32%
120 days
+21.30%

Peer Comparison

Healthcare Equipment & Supplies
Danaher Corp
Danaher Corp
DHR
6.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.98 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
WST
7.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Merit Medical Systems Inc
Merit Medical Systems Inc
MMSI
7.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI